PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer.

Post, Cathalijne C B; Westermann, Anneke M; Bosse, Tjalling; Creutzberg, Carien L; Kroep, Judith R

Post, Cathalijne C B; Westermann, Anneke M; Bosse, Tjalling; Creutzberg, Carien L; Kroep, Judith R.

Afiliação

Post CCB; Departments of Medical Oncology, Leiden, the Netherlands; Departments of Radiation Oncology Leiden, the Netherlands. Electronic address: c.c.b.post@lumc.nl.
Westermann AM; Departments of Medical Oncology, Amsterdam University Medical Centers, Location AMC, Amsterdam, the Netherlands.
Bosse T; Departments of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
Creutzberg CL; Departments of Radiation Oncology Leiden, the Netherlands.
Kroep JR; Departments of Medical Oncology, Leiden, the Netherlands.

Crit Rev Oncol Hematol ; 152: 102973, 2020 Aug.

Article em En | MEDLINE | ID: mdl-32497971

Assuntos

Neoplasias do Endométrio; Antígeno B7-H1; Feminino; Humanos; Imunoterapia; Poli Adenosina Difosfato Ribose; Inibidores de Poli(ADP-Ribose) Polimerases; Receptor de Morte Celular Programada 1; Proteínas

Palavras-chave

Endometrial cancer; Immune checkpoint inhibitor; Immunotherapy; PARP; PD-1; PD-L1; Targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias do Endométrio Limite: Female / Humans Idioma: En Revista: Crit Rev Oncol Hematol Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google